List view / Grid view
11 November 2015 | By Victoria White
Preclinical studies confirm the efficacy of Anisina when delivered using a clinically relevant formulation, mode of administration and dosing regimen...
2 September 2015 | By Victoria White
Novogen has confirmed its scientific review has identified high value opportunities for its technology platforms in areas of unmet patient need...
16 July 2015 | By Victoria White
Novogen has received notification FDA that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma...
14 July 2015 | By Victoria White
A proof of concept study demonstrates Anisina has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects...
24 June 2015 | By Victoria White
Novogen has announced that its candidate cytotoxic chemotherapy drug, Anisina, has proved an effective anti-cancer agent in animals...
14 May 2015 | By Victoria White
Novogen has confirmed that drug candidate, Anisina, is an effective monotherapy against human melanoma in an animal model...
11 May 2015 | By Victoria White
Novogen, in conjunction with Australian paediatric cancer researchers, released key preclinical data on experimental cancer drug-candidate, TRXE-009...
17 April 2015 | By Victoria White
Novogen and the Feinstein Institute for Medical Research are to collaborate to develop effective treatments for brain cancers...
